Zukanorm 100 SR Tablet contains Vildagliptin 100 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Vildagliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Zukanorm 100 SR is formulated as a sustained-release tablet to provide a consistent therapeutic effect over 24 hours, facilitating once-daily dosing and improving patient compliance. It is recommended as monotherapy or in combination with other antidiabetic agents, including metformin, when diet and exercise alone do not achieve adequate glycemic control. Clinical studies have demonstrated that Vildagliptin effectively reduces fasting and postprandial blood glucose levels with a low risk of hypoglycemia and neutral effects on body weight. The medication should be used with caution in patients with renal impairment, and dosage adjustments may be necessary. Common adverse effects include headache, dizziness, and gastrointestinal disturbances. Zukanorm 100 SR Tablet should be prescribed under medical supervision, with regular monitoring of blood glucose and renal function to optimize therapeutic outcomes and minimize potential risks.